Federal Register of Legislation - Australian Government

Primary content

PB 11 of 2011 Lists as made
This instrument amends the National Health (Listing of Pharmaceutical Benefits) Instrument 2010 (No. PB 108 of 2010) to enable the PBS supply of these pharmaceutical benefits for the treatment of skin or soft tissue infections (wound management) where other antimicrobial agents are ineffective or inappropriate. This additional circumstance to prescribe these pharmaceutical benefits is in support of the Queensland Department of Health initiative for the management of wound infections as a result of exposure to bacteria in the flood waters in Queensland.
Administered by: Health
Registered 20 Jan 2011
Tabling HistoryDate
Tabled HR08-Feb-2011
Tabled Senate08-Feb-2011
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

PB 11 of 2011

National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2011
(No. 1)1

National Health Act 1953

I, FELICITY McNEILL, Acting First Assistant Secretary, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under sections 84AF, 85, 85A, 88 and 101 of the National Health Act 1953.

Dated 20 January 2011

 

 

 

 

 

 

 

 

 

 

 

FELICITY McNEILL

Acting First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing


 


1          Name of Instrument

            (1)        This Instrument is the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2011 (No. 1).

            (2)        This Instrument may also be cited as PB 11 of 2011.

2          Commencement

                        This Instrument commences on 20 January 2011.

3          Amendment of PB 108 of 2010

                        Schedule 1 amends PB 108 of 2010.



Schedule 1     Amendments

 

[1] Schedule 1, entry for Ciprofloxacin in the form Tablet 250 mg (as hydrochloride)

omit from the column headed “Circumstances” (all instances):

C1143  C1431  C1432  C1572  C1573

insert:

C1143  C1431  C1432  C1572  C1573  C3680

[2] Schedule 1, entry for Ciprofloxacin in each of the forms: Tablet 500 mg (as hydrochloride); and Tablet 750 mg (as hydrochloride)

omit from the column headed “Circumstances” (all instances):

C1431  C1432  C1572  C1573

insert:

C1431  C1432  C1572  C1573  C3680

[3] Schedule 4, Part 1, entry for Ciprofloxacin

insert after existing text in the columns in the order indicated:

 

C3680

 

For use in skin or soft tissue infections (wound management) where other antimicrobial agents are ineffective or inappropriate

Compliance with Authority Required procedures

 

 

 

 

 

 

 

 

 

1Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 

See http://www.frli.gov.au.